Reverse Translational Research of ABCG2 (BCRP) in Human Disease and Drug Response.
Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, USA.
Institute of Human Genetics, University of California San Francisco, San Francisco, California, USA.
- Published Article
Clinical Pharmacology & Therapeutics
Wiley (Blackwell Publishing)
- Publication Date
Feb 01, 2018
Reverse translational research takes a bedside-to-bench approach, using sophisticated basic research to explain the biological mechanisms behind observed clinical data. For transporters, which play a role in human disease and drug response, this approach offers a distinct advantage over the typical translational research, which often falters due to inadequate in vitro and preclinical animal models. Research on ABCG2, which encodes the Breast Cancer Resistance Protein, has benefited immensely from a reverse translational approach due to its broad implications for disease susceptibility and both therapeutic and adverse drug response. In this review, we describe the success of reverse translational research for ABCG2 and opportunities for further studies. © 2017 American Society for Clinical Pharmacology and Therapeutics.
Report this publication
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
This record was last updated on 10/22/2019 and may not reflect the most current and accurate biomedical/scientific data available from NLM.
The corresponding record at NLM can be accessed at https://www.ncbi.nlm.nih.gov/pubmed/29023674